Liver tests improved most
Thymosin Alpha-1 Research Found Liver Help, Not Sepsis Help
Some liver blood tests improved. The fairest sepsis test did not help patients live longer.
Long-term liver infection had the best results
A long infection can leave you tired while your immune system struggles. Thymosin Alpha-1 is a 28-amino-acid peptide, meaning a short protein built from linked parts.
The clearest gains came in long-term hepatitis B. With the drug added, more patients had blood tests showing less active liver virus [9][12][13].
The biggest and best sepsis test brought no gain in survival [3]. In sepsis, the body's fight against infection can turn deadly.
Cancer and COVID-19 studies gave mixed results. The details show you why firm claims aren't earned.
Thymosin alpha-1 comes from the thymus gland
Behind the breastbone, the thymus trains cells to fight illness. Thymosin alpha-1 is a 28-amino-acid chain, meaning a small protein made from linked parts.
The body clips the smaller protein out of a 113-amino-acid chain. Researchers first found it in calf-thymus batch 5.
In 1977, they listed the order of every part [1]. That list lets makers copy the drug, but it doesn't show that patients improve.
The man-made copy is called thymalfasin. Older people and some patients had less natural protein in their blood, but that doesn't show you need the drug [14].
The Thymosin alpha 1 peptide helps cells find germs
Papers call Thymosin Alpha-1 a peptide, which means a short protein. In lab dishes, the drug helped watchman cells find signs of germs.
One cell message, called interleukin 12, told immune cells to fight. Another, called interleukin 10, told the same cells to ease off.
Those two actions may fight germs while sparing healthy tissue. The idea still doesn't prove that a patient will improve.
The lab team saw both changes only in cells in a dish [5]. That dish study did not show either change making a sick person well.
Ta1 peptide is the same drug, and liver tests improved
Ta1 peptide is a short paper name for Thymosin Alpha-1. One review joined seven fair studies of 535 patients with long-term hepatitis B.
Patients also got interferon, a drug that helps fight viruses. More patients had blood tests showing less active virus, though most reports came from Chinese-language papers [9].
Two more reviews found the same blood-test gain when care included Thymosin Alpha-1 [12][13]. The finding is hopeful, but the body of work is small.
Among patients with scarred livers, the added drug helped more people at first. At 48–52 weeks, the difference between the treatment groups had narrowed [11].
Thymosin alpha 1 covid studies reached different answers
The Thymosin alpha 1 covid work began with a hopeful COVID-19 report. Among 76 very sick patients, deaths were 11.11% with treatment and 30.00% without it.
The report found 3 blood-test changes: more infection-fighting cells and fewer signs that those cells were worn out [6]. Those readings came from 1 small report and didn't prove the drug saved lives.
The early claim leaned heavily on blood results. Blood alone can't tell whether the drug prevented a death.
A 2022 review then joined nine studies covering 5,352 patients. Of those, 1,152 got Thymosin Alpha-1.
Across everyone, the reviewers couldn't show fewer deaths. Signs of possible help appeared after age 60 and among the sickest patients [8].
The best sepsis test found no gain in survival
An early study followed 361 people whose bodies reacted dangerously to infection. Its 28-day death rates were 26.0% with Thymosin Alpha-1 and 35.0% without it.
The 9-point difference favored the drug. The study was too small to rule out chance, though one blood test improved [2].
A larger final-stage test, called phase 3, came next. At 22 hospitals, 1,106 adults received the drug or a placebo.
The placebo looked like the real shot but held no medicine. The 28-day death rates were 23.4% and 24.1%.
Researchers used those death counts to work out where the true result might lie. They were 95% sure it fell between slight help and slight harm, so the study showed no clear benefit [3].
Thymalfasin has not helped cancer patients live longer
Cancer doctors tested thymalfasin, the man-made drug, beside usual cancer care. They hoped for a stronger attack on tumors and less harm from other drugs [7].
The best review was sobering. It covered 26 tests and 2,736 patients.
Several drugs made from thymus tissue were included. The reviewers found no proof that the group helped patients live longer.
Thymosin Alpha-1 also had no clear result for longer life. The reviewers were 95% sure the true answer sat between some help and no help.
Many studies did not make a fair, well-run comparison [10]. That is why the review couldn't claim longer life.
A shot lasting two weeks is still an idea
Fewer needle sticks would be kinder to sore skin. Work from 2024 and 2025 tested ways to release the drug more slowly.
US officials also reviewed whether pharmacies could make it from raw ingredients. The review did not grant FDA approval to thymosin alpha-1.
They considered hepatitis, HIV, COVID-19, vaccines, and several cancers. No use on that list won approval [16].
A 2025 study tested a shot that might release the drug for up to two weeks. During the usual 2-hour span after the peak, the blood amount falls by half, which explains the interest [17].
A slower shot might ease the number of needle sticks someday. It doesn't prove the drug can treat more illnesses.